Wexford Capital LP Sells 23,981 Shares of Standard BioTools Inc. (NASDAQ:LAB)

Wexford Capital LP lessened its holdings in Standard BioTools Inc. (NASDAQ:LAB) by 22.3% during the 3rd quarter, according to its most recent Form 13F filing with the SEC. The fund owned 83,638 shares of the company’s stock after selling 23,981 shares during the period. Wexford Capital LP’s holdings in Standard BioTools were worth $161,000 at the end of the most recent quarter.

A number of other hedge funds also recently bought and sold shares of the business. Vanguard Group Inc. lifted its stake in shares of Standard BioTools by 215.3% in the 1st quarter. Vanguard Group Inc. now owns 13,034,043 shares of the company’s stock valued at $35,322,000 after purchasing an additional 8,900,104 shares during the last quarter. Sumitomo Mitsui Trust Holdings Inc. boosted its stake in Standard BioTools by 20.2% during the second quarter. Sumitomo Mitsui Trust Holdings Inc. now owns 10,642,271 shares of the company’s stock worth $18,837,000 after buying an additional 1,788,780 shares during the period. Hollow Brook Wealth Management LLC purchased a new position in Standard BioTools during the third quarter worth $10,679,000. State Street Corp increased its position in Standard BioTools by 26.7% during the third quarter. State Street Corp now owns 5,495,136 shares of the company’s stock valued at $10,606,000 after acquiring an additional 1,157,984 shares during the last quarter. Finally, Charles Schwab Investment Management Inc. lifted its holdings in shares of Standard BioTools by 188.6% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 2,445,083 shares of the company’s stock worth $4,719,000 after acquiring an additional 1,597,728 shares during the last quarter. Hedge funds and other institutional investors own 53.74% of the company’s stock.

Wall Street Analyst Weigh In

Separately, TD Cowen cut their price target on shares of Standard BioTools from $2.75 to $2.50 and set a “buy” rating on the stock in a report on Thursday, October 31st.

Standard BioTools Stock Performance

LAB opened at $1.82 on Friday. The business has a fifty day moving average of $1.84 and a 200 day moving average of $1.98. Standard BioTools Inc. has a 52-week low of $1.21 and a 52-week high of $3.04.

About Standard BioTools

Standard BioTools Inc, together with its subsidiaries, provides instruments, consumables, reagents, and software services for researchers and clinical laboratories in the Americas, Europe, the Middle East, Africa, and the Asia pacific. It operates through two segments: Proteomics and Genomics. The company offers analytical systems, such as CyTOF XT System, a CyTOF XT mass cytometry system performs automated high-parameter single-cell analysis using antibodies conjugated to metal isotopes; and Hyperion XTi imaging system, a spatial biology instrument.